Cerity Partners LLC Sells 3,523 Shares of Integer Holdings Corporation (NYSE:ITGR)

Cerity Partners LLC lessened its holdings in shares of Integer Holdings Corporation (NYSE:ITGR - Free Report) by 11.3% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 27,658 shares of the medical equipment provider's stock after selling 3,523 shares during the quarter. Cerity Partners LLC owned about 0.08% of Integer worth $3,264,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the business. Capital Research Global Investors lifted its position in shares of Integer by 16.0% during the 4th quarter. Capital Research Global Investors now owns 1,410,803 shares of the medical equipment provider's stock worth $186,960,000 after buying an additional 194,895 shares during the last quarter. Loomis Sayles & Co. L P lifted its position in shares of Integer by 3.8% during the 4th quarter. Loomis Sayles & Co. L P now owns 558,715 shares of the medical equipment provider's stock worth $74,041,000 after buying an additional 20,688 shares during the last quarter. Congress Asset Management Co. lifted its position in shares of Integer by 4.9% during the 1st quarter. Congress Asset Management Co. now owns 522,656 shares of the medical equipment provider's stock worth $61,679,000 after buying an additional 24,306 shares during the last quarter. Driehaus Capital Management LLC lifted its position in shares of Integer by 5.5% during the 4th quarter. Driehaus Capital Management LLC now owns 451,464 shares of the medical equipment provider's stock worth $59,828,000 after buying an additional 23,706 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Integer by 14.2% in the 4th quarter. Northern Trust Corp now owns 422,380 shares of the medical equipment provider's stock valued at $55,974,000 after acquiring an additional 52,556 shares during the period. Institutional investors and hedge funds own 99.29% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on ITGR shares. Truist Financial set a $150.00 price objective on shares of Integer and gave the company a "buy" rating in a research note on Friday, April 25th. Benchmark lowered their price target on shares of Integer from $150.00 to $140.00 and set a "buy" rating on the stock in a research note on Friday, April 25th. Citigroup raised shares of Integer from a "hold" rating to a "strong-buy" rating and upped their price target for the stock from $133.00 to $140.00 in a research note on Thursday, May 22nd. Raymond James Financial upped their price target on shares of Integer from $145.00 to $150.00 and gave the stock an "outperform" rating in a research note on Friday, April 25th. Finally, Wall Street Zen upgraded shares of Integer from a "sell" rating to a "hold" rating in a research report on Monday, May 19th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Integer currently has a consensus rating of "Moderate Buy" and a consensus target price of $146.25.

Integer Stock Performance

ITGR stock traded up $3.14 during mid-day trading on Tuesday, reaching $114.69. The company had a trading volume of 563,399 shares, compared to its average volume of 390,074. The company has a quick ratio of 2.14, a current ratio of 3.40 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $4.00 billion, a P/E ratio of 54.35, a P/E/G ratio of 0.96 and a beta of 0.98. Integer Holdings Corporation has a one year low of $104.93 and a one year high of $146.36. The stock's 50-day simple moving average is $119.65 and its two-hundred day simple moving average is $124.34.

Integer (NYSE:ITGR - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The medical equipment provider reported $1.31 earnings per share for the quarter, beating analysts' consensus estimates of $1.27 by $0.04. Integer had a net margin of 4.38% and a return on equity of 11.95%. The business had revenue of $437.39 million for the quarter, compared to analysts' expectations of $428.51 million. During the same period in the previous year, the business earned $1.14 earnings per share. The company's revenue was up 7.3% on a year-over-year basis. Research analysts anticipate that Integer Holdings Corporation will post 6.01 EPS for the current year.

Insider Buying and Selling

In related news, Director Martin C. Maxwell sold 8,720 shares of Integer stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $120.56, for a total value of $1,051,283.20. Following the transaction, the director owned 22,170 shares of the company's stock, valued at approximately $2,672,815.20. This trade represents a 28.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Joseph W. Dziedzic sold 338,975 shares of Integer stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $123.17, for a total value of $41,751,550.75. Following the completion of the transaction, the chief executive officer directly owned 47,000 shares in the company, valued at $5,788,990. This represents a 87.82% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 362,434 shares of company stock valued at $44,577,115 over the last three months. Company insiders own 2.16% of the company's stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.